MUMBAI, India, July 5 -- Intellectual Property India has published a patent application (202311085702 A) filed by Translational Health Science And Technology Institute, Faridabad, Haryana, on Dec. 15, 2023, for 'method for preparation of molecular assay and device for detection of oncological disorders.'
Inventor(s) include Dr. Jayanti Kumari; Dr. Niya Mathur; Kumar Nishchaya; Mehak Bajaj; Devhuti Chetan Palan; Dr. Susmita Chaudhuri; Dr. Niraj Kumar; Dr. Chaitali Singhal; Dr. Sagnik Chakraborty; Dr. Shinjini Bhatnagar; and Dr. Jayanta Bhattacharya.
The application for the patent was published on July 4, under issue no. 27/2025.
According to the abstract released by the Intellectual Property India: "A method for preparing a molecular assay that may be used in a lateral flow (LFA) device, semi-quantitative in nature, for detecting oncological disorders is disclosed. The method involves the preparation of an anti-Interleukin-8 monoclonal antibodies and an anti-LGALS3BP monoclonal antibodies. Gold nanoparticles (AuNPs) are synthesized via a chemical reduction process and functionalized by attaching streptavidin to form a versatile conjugation platform. The anti-IL-8 mAb is first conjugated to the gold nanoparticles, creating AuNP anti-IL-8 mAb conjugates. Subsequently, the anti-LGALS3BP mAb is conjugated to form AuNP anti LGALS3BP mAb conjugates. These dual-functionalized nanoparticle conjugates serve as sensitive diagnostic tools for oncological applications, enabling targeted detection of biomarkers. The method ensures high specificity and stability of the molecular assay and henceforth developed conjugates, providing significant potential for use in clinical diagnostics and research."
Disclaimer: Curated by HT Syndication.
